Follow the people · Insider
Filip Janku
Filip Janku files insider transactions with the SEC as a chief medical officer of Monte Rosa Therapeutics (GLUE). We hold 6 disclosed purchases and sales filed since 25 June 2021, 4 of them in the last 90 days.
- Files forGLUE
- Disclosed buys and sells6 in all, 4 in the last 90 days
- Last disclosure1 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 23 June 2021 — 30 June 2026Chief Medical Officer · Monte Rosa Therapeutics (GLUE)29 Form 4 lines · source: SEC Form 4
Everything they disclosed
29 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 5,407 shares of Monte Rosa TherapeuticsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- ▼ sold on the open market 5,407 shares of Monte Rosa TherapeuticsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- exercised options over 5,407 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 1 July 2026
- exercised options over 6,000 shares of Monte Rosa TherapeuticsSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 6,000 shares of Monte Rosa TherapeuticsSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- exercised options over 6,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 430 June 2026Stock Option (Right to Buy) · traded 29 June 2026 · filed 30 June 2026
- exercised options over 6,000 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- ▼ sold on the open market 11,845 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 30,000 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 24 June 2026 · filed 25 June 2026
- ▼ sold on the open market 30,000 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 24 June 2026 · filed 25 June 2026
- exercised options over 6,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 23 June 2026 · filed 25 June 2026
- exercised options over 30,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 24 June 2026 · filed 25 June 2026
- ▼ sold on the open market 9,189 shares of Monte Rosa TherapeuticsSEC Form 424 February 2026Common Stock · traded 23 February 2026 · filed 24 February 2026
- ▼ sold on the open market 9,189 shares of Monte Rosa TherapeuticsSEC Form 424 February 2026Common Stock · traded 23 February 2026 · filed 24 February 2026
- was granted 31,000 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 3,155 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 5 January 2026 · filed 5 January 2026
- was granted 139,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 5 January 2026
- was granted 139,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 5 January 2026
- was granted 31,000 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 3,155 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 5 January 2026 · filed 5 January 2026
- was granted 161,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 46 January 2025Stock Option (Right to Buy) · traded 2 January 2025 · filed 6 January 2025
- was granted 36,000 shares of Monte Rosa TherapeuticsSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 30,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 13 September 2024 · filed 13 September 2024
- was granted 121,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 44 January 2024Stock Option (Right to Buy) · traded 2 January 2024 · filed 4 January 2024
- was granted 135,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 44 January 2023Stock Option (Right to Buy) · traded 3 January 2023 · filed 4 January 2023
- was granted 36,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 419 December 2022Stock Option (Right to Buy) · traded 15 December 2022 · filed 19 December 2022
- was granted 36,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 41 November 2022Stock Option (Right to Buy) · traded 31 October 2022 · filed 1 November 2022
- was granted 86,500 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 42 March 2022Stock Option (Right to Buy) · traded 1 March 2022 · filed 2 March 2022
- was granted 387,069 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 425 June 2021Stock Option (Right to Buy) · traded 23 June 2021 · filed 25 June 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.